FPROPELLER Trial Results – SAR-bisPSMA Safe, Well Tolerated and Efficacious in the Detection of Prostate Cancer
Clarity Pharmaceuticals (ASX: CU6)
(“Clarity”), a clinical-stage radiopharmaceutical company with a mission to
develop next-generation products that improve treatment outcomes for children
and adults with cancer, is pleased to announce favourable imaging data from its
Phase I diagnostic trial of 64Cu SAR-bisPSMA in prostate cancer, PROPELLER (NCT
048393671)1. This follows the announcement of top line data in December 2022.
This data is currently being presented
via a poster at the American Society of Clinical Oncology (ASCO) Genitourinary
(GU) Symposium in San Francisco. The poster will be available on Clarity’s
website once released at ASCO GU.
To read more please visit:
Source: Clarity